Thu, Nov 5, 2026
[Archive]
Articles In Press
Back to the articles list |
Back to browse issues page
Effat Partovinezhad1 
, Hamid Khederlou *2 , Mohammad Mohsenpour Sisi1 , Narges Mohammadi1 , Mobina Ghajar1
, Hamid Khederlou *2 , Mohammad Mohsenpour Sisi1 , Narges Mohammadi1 , Mobina Ghajar1
1- Zanjan University of Medical Sciences, Zanjan, Iran.
2- Cardiology Department, Zanjan University of Medical Sciences, Zanjan, Iran. ,dr.khederlou@gmail.com
2- Cardiology Department, Zanjan University of Medical Sciences, Zanjan, Iran. ,
Abstract: (585 Views)
Background: ST-elevation myocardial infarction (STEMI) is a major cardiovascular emergency. Left ventricular ejection fraction (EF) is a critical predictor of prognosis post-STEMI. Diabetes mellitus (DM), especially newly diagnosed, may influence cardiac function.
Methods: This cross-sectional study included 283 patients admitted with STEMI. Demographic, clinical, laboratory data, angiographic data, and EF were collected. DM was screened with HbA1C, and EF was evaluated by transthoracic 2D echocardiography. Statistical analyses were performed by SPSS 26.
Results: Among 1562 patients following refer with acute coronary syndrome (ACS), 283 patients with STEMI and without exclusion criteria were entered to present study. Mean age was 63.1 ± 10.5years. The patients with reduced EF were significantly older (61.4 ± 9.8 years vs 67.2 ± 10.8 years; P-value<0.001). A statistically significant association was found between new diagnosed DM and reduced EF (P-value=0.037). Smoking was also significantly associated with reduced EF (P-value=0.023). No significant association was found between EF and body mass index (BMI), sex, hypertension (HTN), dyslipidemia (DLP), coronary artery disease (CAD) severity, culprit lesion, and MI territory, .
Conclusion: New DM, older age, and smoking are significantly associated with reduced EF in patients with STEMI.
Methods: This cross-sectional study included 283 patients admitted with STEMI. Demographic, clinical, laboratory data, angiographic data, and EF were collected. DM was screened with HbA1C, and EF was evaluated by transthoracic 2D echocardiography. Statistical analyses were performed by SPSS 26.
Results: Among 1562 patients following refer with acute coronary syndrome (ACS), 283 patients with STEMI and without exclusion criteria were entered to present study. Mean age was 63.1 ± 10.5years. The patients with reduced EF were significantly older (61.4 ± 9.8 years vs 67.2 ± 10.8 years; P-value<0.001). A statistically significant association was found between new diagnosed DM and reduced EF (P-value=0.037). Smoking was also significantly associated with reduced EF (P-value=0.023). No significant association was found between EF and body mass index (BMI), sex, hypertension (HTN), dyslipidemia (DLP), coronary artery disease (CAD) severity, culprit lesion, and MI territory, .
Conclusion: New DM, older age, and smoking are significantly associated with reduced EF in patients with STEMI.
Type of Study: Case Report Article |
Subject:
Clinical Medicine
Received: 2025/10/3 | Accepted: 2026/08/16
Received: 2025/10/3 | Accepted: 2026/08/16
References
1. Bak J , Aguayo-Ortiz R, Rathod N, PrimeauJ, Bashir KhanM, Robia S, et al. Primitive phospholamban- and sarcolipin-like peptides inhibit the sarcoplasmic reticulum calcium pump SERCA. Biochemistry. 2022; 61(14): 1419-30. [DOI:10.1021/acs.biochem.2c00246] [PMID] [PMCID]
2. Martens P, Nijst P , Verbrugge F, Dupont M, Tang W , Mullens W.Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. Heart Rhythm, 2018. 15(1): 130-36. [DOI:10.1016/j.hrthm.2017.08.021] [PMID]
3. Lam C , McEntegart M, Claggett B, Liu J, Skali H, Lewiset E,et al. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the valsartan in acute myocardial infarction trial (VALIANT). Eur J Heart Fail. 2015; 17(3): 301-12. [DOI:10.1002/ejhf.238] [PMID]
4. Khederlou H, Azimi Pirsaraei V, Rabbani E, Motedayen M.Correlations between cardiovascular risk factors and ventricular arrhythmias following primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. J Tehran Heart Cent. 2023. 18(2): 122-28. [DOI:10.18502/jthc.v18i2.13322]
5. Almoros L, Cepeda-Rodrigo J, Lorenzo O. Diabetic cardiomyopathy. Rev Clin Esp (Barc). 2022; 222(2): 100-11. [DOI:10.1016/j.rceng.2019.10.012] [PMID]
6. Paolillo S, Marsico F, Prastaro M , Renga F, Esposito L, Martino F,et al. Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Fail Clin. 2019; 15(3): 341-47. [DOI:10.1016/j.hfc.2019.02.003] [PMID]
7. Ding Q, Spatz E , Lipska K, Lin H , Spertus J, P Dreyer R,et al. Newly diagnosed diabetes and outcomes after acute myocardial infarction in young adults. Heart. 2021; 107(8): 657-66. [DOI:10.1136/heartjnl-2020-317101] [PMID] [PMCID]
8. Pan W, Lu H, Lian B, Liao P, Guo L, Zhang M.Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019; 18(1): 169. [DOI:10.1186/s12933-019-0970-6] [PMID] [PMCID]
9. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27): 1718-27. [DOI:10.1093/eurheartj/ehv134] [PMID]
10. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia, 2018. 61(1): 21-28. [DOI:10.1007/s00125-017-4390-4] [PMID]
11. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity. Circ Res. 2018. 122(4): 624-38. [DOI:10.1161/CIRCRESAHA.117.311586] [PMID]
12. Avagimyan A, Popov S, Shalnova S. The pathophysiological basis of diabetic cardiomyopathy development. Curr Probl Cardiol, 2022. 47(9): 101156. [DOI:10.1016/j.cpcardiol.2022.101156] [PMID]
13. Kowalczyk J, Mazurek M, Zielinska T, Lenarczyk R, Sedkowska A, Swiatkowski A,et al. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol. 2015; 22(6): 798-806. [DOI:10.1177/2047487314527850] [PMID]
14. Liu J , Zhou Y, Huang H, Liu R, Kang Y, Zhu T,et al. Impact of stress hyperglycemia ratio on mortality in patients with critical acute myocardial infarction: insight from american MIMIC-IV and the chinese CIN-II study. Cardiovasc Diabetol. 2023;22(1): 281. [DOI:10.1186/s12933-023-02012-1] [PMID] [PMCID]
15. Wereski R, Kimenai D, Bularga A, Taggart C, Lowe D, Mills N,et al. Risk factors for type 1 and type 2 myocardial infarction. Eur Heart J. 2022; 43(2): 127-35. [DOI:10.1093/eurheartj/ehab581] [PMID] [PMCID]
16. Ma Y, Gao H, Wu H. Comparison of adverse cardiovascular event endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques: a systematic review and meta-analysis. J Cardiothorac Surg. 2024; 19(1): 672. [DOI:10.1186/s13019-024-03157-0] [PMID] [PMCID]
17. Ghoreyshi-Hefzabad SM, Jeyaprakash P, Vo H , Gupta A, Ozawa K, Pathan F,et al. Subclinical systolic dysfunction detected by 2D speckle tracking echocardiography in adults with diabetes mellitus: systematic review and meta-analysis of 6668 individuals with diabetes mellitus and 7218 controls. Int J Cardiovasc Imaging. 2023; 39(5): 977-89. [DOI:10.1007/s10554-023-02810-4] [PMID] [PMCID]
18. Ritchie RH, Abel E. Basic mechanisms of diabetic heart disease. Circ Res. 2020. 126(11): 1501-25. [DOI:10.1161/CIRCRESAHA.120.315913] [PMID]
19. Heather L, Gopal K, Srnic N, Ussher J,et al. Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology. Diabetes. 2024; 73(5): 659-70. [DOI:10.2337/dbi23-0019] [PMID] [PMCID]
20. Yubero-Serrano EM, Perez-Martinez P. Advanced glycation end products and their involvement in cardiovascular disease. Angiology. 2020. 71(8): 698-700. [DOI:10.1177/0003319720916301] [PMID]
21. Sorrentino A, Borghetti G, Zhou Y, Cannata A, Meo M, Signore S, et al. Hyperglycemia induces defective Ca2+ homeostasis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2017; 312(1): H150-H161. [DOI:10.1152/ajpheart.00737.2016] [PMID] [PMCID]
22. Jankauskas S, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A,et al. Heart failure in diabetes. Metabolism. 2021; 125: 154910. [DOI:10.1016/j.metabol.2021.154910] [PMID] [PMCID]
23. Mei Ma X, Geng K, Wang P , Jiang Z, Yuen-Kwan Law B, Xu Y. MCT4-dependent lactate transport: a novel mechanism for cardiac energy metabolism injury and inflammation in type 2 diabetes mellitus. Cardiovasc Diabetol. 2024. 23(1): 96. [DOI:10.1186/s12933-024-02178-2] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
Journal of Advances in Medical and Biomedical Research by Zanjan University of Medical Sciences is licensed under CC BY-NC 4.0
